DMAA
Drugs Made In America Acquisition Corp.
Key Financials
Net Income
$5.9M
↑ 2222.8%
Operating Income
$-2816013
↓ 906.3%
Total Liabilities
$7.3M
↑ 814.5%
Shareholders' Equity
$-7263981.00
↓ 2866.8%
EPS (Diluted)
$-0.03
N/A
Cash & Equivalents
$14887.00
N/A
Total Assets
$239.9M
↑ 43456.4%
Operating Cash Flow
$-539187.00
↓ 213.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/14/2026 | View on SEC |
| SCHEDULE 13G | 5/14/2026 | View on SEC |
| 425 | 5/5/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| 8-K | 5/1/2026 | View on SEC |
| 8-K | 4/28/2026 | View on SEC |
| DEFR14A | 4/16/2026 | View on SEC |
| 10-K | 4/15/2026 | View on SEC |
| DEF 14A | 4/14/2026 | View on SEC |
| 8-K | 4/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DMAA |
| Company Name | Drugs Made In America Acquisition Corp. |
| CIK | 2028614 |
| Sector | Blank Checks |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 6770 |
| SIC Description | Blank Checks |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 646-726-7074 |